Juniper Pharma Services continues its strategic capital investment in oral solid dose services

3 weeks ago

Nottingham, UK – Juniper Pharma Services (JPS), a Contract Development and Manufacturing Organisation (CDMO) specialising in the development of challenging small molecules, is continuing its strategic investment in oral solid dose manufacturing with a $1.7m purchase of three additional pieces of processing equipment. This investment enhances JPS’ commitment to rapidly transform promising molecules into successful

Juniper Pharma Services expands laboratory facilities to meet with growing demand

1 month ago

Nottingham, UK – Juniper Pharma Services (JPS), a Contract Development and Manufacturing Organisation (CDMO) specialising in the development of challenging small molecules, has announced a significant expansion to its UK-based drug development and clinical trial manufacturing facilities. The extension provides four additional process development laboratories at its Nottingham site, improving the output and efficiency of

Juniper Pharma Services to Participate in Inaugural West Coast Advancing Drug Development Forum

1 month ago

Nottingham, UK – Juniper Pharma Services (JPS), a Contract Development and Manufacturing organisation (CDMO) specialising in the development of challenging small molecules, will be attending the 2nd ‘Advancing Drug Development Forum (ADDF) – Making the Impossible, Possible.’ on June 14th at the San Francisco Wine School, California. JPS will be joining key opinion leaders at

Biotech Outsourcing Strategies Congress (BOS), Basel 19-20 June 2018

2 months ago

Juniper is delighted to be Gold Sponsor of the annual Biotech Outsourcing Strategies event in Basel, Switzerland, from 19th to 20th June 2018. We will be joining thought leaders in the industry to share experience and knowledge from early stage discovery into late product development. On Wednesday 20th June, at 4.20 p.m, Ms Gudrun Fridgeirsdottir,

Advancing Drug Development Forum, San Francisco 14 June 2018

3 months ago

The Advancing Drug Development Forum has confirmed a prestigious line-up of leading industry voices to speak at its inaugural West Coast event ‘Advancing Drug Development Forum – Making the Impossible, Possible’, on June 14, 2018 at the San Francisco Wine School in South San Francisco, CA. Juniper will be joining key opinion leaders in biotech

4th Annual Formulation & Drug Delivery Congress, London 8-9 May 2018

3 months ago

Juniper will be joining a line-up of industry experts at the 4th Annual Formulation & Drug Delivery Congress in London, 8-9 May 2018. Focusing on key innovation in formulation and drug delivery, Dr. Rob Harris, Chief Technical Officer at Juniper Pharma Services, will be chairing the “Advances in Drug Delivery” stream 2 on 8th May.

Interphex, New York April 17-19 2018

4 months ago

Juniper Pharma Services is attending International Pharmaceutical Expo (INTERPHEX), Booth #4115, April 17-19, within the new “Formulation X” section of the event at the Javits Centre in New York. Interphex is the premier event dedicated to pharmaceutical and biotechnology innovation, technology and knowledge from development through commercialisation. The event will bring together inspired professionals with

Spray Drying ECA Conference, Lisbon 10-12 April 2018

4 months ago

Juniper is attending the Spray Drying ECA Conference in Lisbon 10-12 April 2018. Dr Andrew Parker will be presenting on the “Application of spray dried materials in the pharmaceutical industry” at the ECA – European GMP Conference on  Spray Drying in Lisbon, 10-12 April 2018. He will discuss the challenges in pharmaceutical development for small

7th Drug Formulation, Solubility & Bioavailability Summit, Boston 26-28 March, 2018

4 months ago

Juniper will be attending the 7th Drug Formulation, Solubility & Bioavailability Summit in Boston 26-28 March, 2018. Join us to discuss the latest formulation strategies and predictive technologies to accelerate manufacturing, preclinical R&D and time to market. When over 80% of APIs in development are poorly water-soluble, drug companies must rely increasingly on new formulation

Accelerating Paediatric Formulation Development, London 28 March 2018

4 months ago

Wednesday 28th March 2018 – Friends House, Euston Road, London Update on Contemporary Paediatrics and Presentation of Output from SPaeDD-UK Project* The Smart Paediatric Drug Development (SPaeDD) initiative co-funded by Innovate UK (the UK’s Innovation Agency) is a cross company and academic centre initiative to accelerate paediatric formulation development. Established in 2014 and focussed on